13F Holdings
中文EN

IRLA IRulya Therapeutics Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1662774 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-87.4%
TTM EPS YoY193.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-98.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets26.6%
Debt / equity—
Current ratio14.72x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.44x
Accruals ratio-55.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$35.38M$18.59M$9.45M$25.18M$60.80M
SG&A expense$15.05M$17.58M$17.70M$26.01M$29.52M
Operating income-$58.07M-$57.28M-$34.62M-$52.02M-$90.32M
Pretax income-$80.77M-$56.74M-$31.58M-$51.94M-$89.94M
Income tax$3.21M$87,000-$197,000-$284,000$0
Net income-$83.98M-$56.83M-$31.39M-$51.66M-$89.94M
EBITDA-$57.93M-$57.10M-$34.30M-$51.81M-$89.97M
EPS (basic)-1.68-1.31-0.84-1.54-3.03
EPS (diluted)-1.68-1.31-0.84-1.54-3.03
Weighted avg. shares (diluted)50.10M43.26M37.24M33.50M29.72M
Balance sheet
Cash & equivalents$5.81M$6.21M$20.75M$44.58M$69.72M
Short-term investments$11.94M$34.57M$54.31M$45.60M$37.08M
Receivables———$0—
Current assets$22.90M$44.04M$77.44M$93.75M$111.67M
PP&E, net$595,000$315,000$234,000$393,000$263,000
Goodwill—$0$17.62M$0$0
Intangibles$67.82M$60.05M$63.67M$5.90M$0
Total assets$93.52M$114.48M$167.90M$103.91M$133.23M
Current liabilities$43.23M$7.28M$9.57M$3.07M$14.22M
Short-term debt$18.03M$0———
Long-term debt$0$14.32M$13.43M$0—
Total debt$18.03M$14.32M$13.43M$0—
Total liabilities$129.24M$84.33M$82.82M$3.32M$14.64M
Shareholders' equity-$35.71M$30.15M$85.08M$100.59M$118.59M
Net debt$12.22M$8.11M-$7.32M-$44.58M—
Shares outstanding278,62744.00M42.97M36.14M30.07M
Cash flow statement
Operating cash flow-$41.42M-$31.90M-$18.29M-$44.04M-$62.93M
Capital expenditure$352,000$257,000$160,000$133,000$180,000
Free cash flow-$41.78M-$32.16M-$18.45M-$44.17M-$63.11M
Investing cash flow$23.23M$21.91M-$5.76M$18.00M$58.95M
Financing cash flow$17.91M-$4.78M$143,000$707,000$6.81M
Depreciation & amortization$142,000$186,000$322,000$204,000$344,000
Stock-based compensation$5.11M$4.75M$5.22M$16.62M$29.85M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.